Eden Research Share Discussion Threads

[supersonico] 08/5/2024 22:20

Any thoughts on what the up front / milestone pre sales payments might look like given the NDA'S in place prior to announcement?

[alchemy] 08/5/2024 14:52

What multiple of market size is insecticide against our current target markets ?

[neutralpov] 08/5/2024 12:59

Alchemy:
Someone as MIND-NUMBINGLY THICK as you shouldn't be anywhere near the stockmarket.

Even "remotely near"!

I feel physically unclean to be on the same forum as morons like you and Timbo_Slice.

Please show this message to your handler.

[alchemy] 08/5/2024 11:18

1.1 million in half year 23 - announced late September ! Sainthood awaits us all .

[alchemy] 08/5/2024 11:12

Views on FY 24 turnover. Cavendish at 5 millionModest or not?Next data point on revenue half year results . So August ? And paraphrasing Invrstor what will start the jazz concert ? Cos it's monotone white noise at the moment

[neutralpov] 08/5/2024 10:14

Investingisatrickygame 8 May '24 - 09:24 - 17552
[[ SNIP!! ]]

FOAD, perv.

You think we don't know about your addiction?

And I don't mean the kiddiepron.

[babysitter] 08/5/2024 09:27

MW retired and closed site down.

[investingisatrickygame] 08/5/2024 09:24

Eden needs appetite for its shares, something that is sadly lacking and frankly, has been for years. That is undeniable. Michael Walters, strong supporter of Eden that he was/is, is not going to propel the share price forward.

New actions are needed to resonate with the investor community.

[sandcrab2] 08/5/2024 08:41

What's happened to Michael Walters?

[alchemy] 07/5/2024 19:38

I have read the Cavendish note.Like the content of the RNS I think it's a "route confirmation" note.I was disappointed that Cavendish is thinking £5million for FY24.3:2 to 5 following 1.8 to 3.2.1.8 delta plays 1.4 and , given new products and new markets, that seems an easy stretch to me.More pebbles needed into the pool. A big pebble would be insecticide causing a big splash.The splash in revenue not til FY 25? But discountable?

[supersonico] 07/5/2024 15:43

He can't Say Cedroz and gives no credit for the inthecoming Global Insecticide deal.

Not a Serious Lube.

[supersonico] 07/5/2024 15:41

'there's nothing to indicate that things will change next year'

Not a serious Lube as I have come to expect from Fraudy Lube grifters.

[supersonico] 07/5/2024 13:10

Says the fella who valued his own posting so much he deleted all his Eden history and still can't say Cedroz.

Not the brightest Lube in the Tube.

[jaknife] 07/5/2024 13:00

The biggest dog on AIM reports its final results. Some quick notes:

P&L
* Revenue up 75%
* But still a stonking £1.9m operating loss
* Revenue needs to increase by c. 106% to get to P&L breakeven
* Yet another impairment review, £5m written off intangibles in acknowledgement that the previous policy on capitalising intangibles was too aggressive
* Total loss of £6.5m, equivalent to 1.54p a share, more than a third of the current share price!

Balance Sheet
* Net assets of £13.5m
* £7.4m of cash so no need to raise funds ... yet


Cash Flow
* £1.65m of expenses capitalised directly to the P&L, which explains why cash flow is so much worse than P&L
* The total loss would have been £8m if costs had gone through the P&L instead
* How long before these intangibles are also written off?
* Allowing for these extra costs then revenue needs to increase by c. 300% to get to cash flow breakeven


Other
* Note 7 shows grossly excessive "snouts in the trough" director remuneration.
* How on earth can bonuses be due when the company has lost so much?


All in all it's another poor year (is that 18 straight years of losses?) and there's nothing to indicate that things will change next year. But there's probably enough cash to keep them going for 2024 and 2025 so another placing probably won't be needed until 2026. Can they get a mug journalist to tip the shares and get suckers to buy in advance of the next placing?

JakNife

[supersonico] 07/5/2024 11:46

I have many questions.

One question I have is ..will we see an RNS with Wheat in the title before we see one with Syngenta ??..

[neutralpov] 07/5/2024 11:41

> Derek McAllan

ROTFLMAOOOOOOOOOOOOOOOOOOOOOOOOO!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!1

;D

And these fluxwits here in this DB *STILL* keep on holding....

"multibagger" HAHAAHAHAHAHAHAHAAAAAHHHAAAAAAAAAAAAAAA!!!!

;D

Sectioning needed, pronto.

[supersonico] 07/5/2024 09:35

Mattie Pogorzelski Senior Supply Chain Manager recently left his role..I'm waiting to see to if this position will be enhanced to reflect the growing dynamics and complexity of Eden sales going forward.

[investingisatrickygame] 07/5/2024 09:29

Lykele "From my years of experience in the crop protection industry, I can assure you that taking a product from an idea into the market in under four years is quite exceptional." AND "I remain very optimistic about Eden's future prospects and it becoming a leader in biological crop protection products and solutions."

Sean "Our focus over the medium term will be bringing the business to profitability" AND "just after the year-end, Californian authorities granted approval for Mevalone. This led to a sizeable order fulfilment for Eden's US distribution partner, Sipcam Agro USA, setting the stage for significantly more sales of Mevalone to come in the US in 2024."

AND "Additionally, a significant proportion of the net proceeds from the conditional capital raise of £7.7m will be dedicated towards the development efforts for our bio-insecticide"

All very positive

[alchemy] 07/5/2024 09:27

Cavendish note -Fruitful Year the title

[monet] 07/5/2024 09:07

Appointment of Non-Executive Director



Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and a plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, is pleased to announce the appointment of Derek McAllan as a Non-Executive Director of the Company with immediate effect.



Derek is currently a Partner of RSM UK, a leading provider of audit, tax and consulting services in the UK, where he is responsible for business development and client service across a portfolio of companies. Prior to his move to RSM UK in 2020, Derek acted as a Partner at KPMG for seventeen years during which he had a significant number of life science clients including some with which he worked from their inception to ultimate exit (including listings on NASDAQ and AIM, and also trade sales).

[supersonico] 07/5/2024 08:25

Solid progress and nothing too exciting yet and not the one that mentions Syngenta..